Safety of IV meropenem in pediatric OPAT
Abstract:
Background: Outpatient parenteral antimicrobial therapy (OPAT) is often used for patients who need long-term antimicrobial therapy. Meropenem is a broad-spectrum antibiotic used to treat polymicrobial and multidrug-resistant bacterial infections.
Objective: To evaluate the efficacy, tolerance, and safety of IV meropenem for pediatric patients in the OPAT program at CHU Sainte-Justine in Montréal, Quebec.
Methods: At the study institution, meropenem solutions (1-40 mg/mL) are prepared in polyvinylchloride bags or cassettes. Each delivery device contains one daily dose, and infusions (at room temperature) take place every 8 hours. Devices are delivered to the patient’s home in batches every 3 or 4 days. With refrigeration, the drug solution has a short period of stability (96 hours). This single-centre retrospective study included all patients under 18 years of age who received IV meropenem therapy as part of the OPAT program between April 2000 and April 2024. For the current analysis, demographic data, clinical data, serum alanine aminotransferase levels, and white blood cell counts were collected using a standardized template.
Results: A total of 349 courses of therapy (for 262 patients) met the inclusion criteria. For most patients, the treatments were successful and well tolerated, with an overall success rate of 93.4% (326/349). Few gastrointestinal symptoms and rashes were reported. Neutropenia and eosinophilia were more frequently observed than in previous studies. OPAT-related adverse events were mainly catheter-related (8.9%, 31/349) or pump-related (6.3%, 22/349) issues.
Conclusions: These results suggest that IV meropenem can be safely and effectively used in pediatric OPAT, although the target concentration of 90% may not be retained, according to current stability data.
Reference:
Yu S, Tremblay S, Coïc L, Bérard C, Martineau-Cyr PA, Forest JM, Chagnon J, Ovetchkine P, Tapiéro B. Effectiveness, Tolerance, and Safety of Meropenem in a Pediatric Outpatient Parenteral Antimicrobial Therapy Program. Can J Hosp Pharm. 2025 Jul 9;78(3):e3772. doi: 10.4212/cjhp.3772. PMID: 40584927; PMCID: PMC12204710.